vs
EXACT SCIENCES CORP（EXAS）与SLM Corp（SLM）财务数据对比。点击上方公司名可切换其他公司
EXACT SCIENCES CORP的季度营收约是SLM Corp的1.6倍（$878.4M vs $560.0M），SLM Corp净利率更高（55.0% vs -9.8%，领先64.8%），过去两年SLM Corp的营收复合增速更高（22.7% vs 17.4%）
Exact Sciences是总部位于美国威斯康星州麦迪逊的分子诊断企业，专注于早期癌症检测领域。公司核心产品覆盖结直肠癌筛查与预防场景，其中Cologuard是全球首个获批的结直肠癌粪便DNA检测产品，同时还提供其他多种癌症的筛查服务及精准肿瘤检测解决方案。
尼康旗下SLM Solutions AG总部位于德国吕贝克，是金属3D打印机领域的上市生产商，共同拥有SLM文字商标，集团股份自2014年5月9日起在法兰克福证券交易所高级市场板块挂牌交易。
EXAS vs SLM — 直观对比
营收规模更大
EXAS
是对方的1.6倍
$560.0M
净利率更高
SLM
高出64.8%
-9.8%
两年增速更快
SLM
近两年复合增速
17.4%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $878.4M | $560.0M |
| 净利润 | $-86.0M | $308.0M |
| 毛利率 | 70.1% | — |
| 营业利润率 | -9.4% | 69.6% |
| 净利率 | -9.8% | 55.0% |
| 营收同比 | 23.1% | — |
| 净利润同比 | 90.1% | 1.0% |
| 每股收益（稀释后） | $-0.45 | $1.54 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EXASSLM
| Q1 26 | — | $560.0M | ||
| Q4 25 | $878.4M | $377.1M | ||
| Q3 25 | $850.7M | $373.0M | ||
| Q2 25 | $811.1M | $376.8M | ||
| Q1 25 | $706.8M | $375.0M | ||
| Q4 24 | $713.4M | $362.2M | ||
| Q3 24 | $708.7M | $359.4M | ||
| Q2 24 | $699.3M | $372.2M |
净利润EXASSLM
| Q1 26 | — | $308.0M | ||
| Q4 25 | $-86.0M | $233.2M | ||
| Q3 25 | $-19.6M | $135.8M | ||
| Q2 25 | $-1.2M | $71.3M | ||
| Q1 25 | $-101.2M | $304.5M | ||
| Q4 24 | $-864.6M | $111.6M | ||
| Q3 24 | $-38.2M | $-45.2M | ||
| Q2 24 | $-15.8M | $252.0M |
毛利率EXASSLM
| Q1 26 | — | — | ||
| Q4 25 | 70.1% | — | ||
| Q3 25 | 68.6% | — | ||
| Q2 25 | 69.3% | — | ||
| Q1 25 | 70.8% | — | ||
| Q4 24 | 69.0% | — | ||
| Q3 24 | 69.4% | — | ||
| Q2 24 | 69.8% | — |
营业利润率EXASSLM
| Q1 26 | — | 69.6% | ||
| Q4 25 | -9.4% | 83.8% | ||
| Q3 25 | -3.0% | 49.8% | ||
| Q2 25 | -0.3% | 23.3% | ||
| Q1 25 | -13.6% | — | ||
| Q4 24 | -122.8% | 36.5% | ||
| Q3 24 | -5.6% | -16.6% | ||
| Q2 24 | -3.8% | 91.0% |
净利率EXASSLM
| Q1 26 | — | 55.0% | ||
| Q4 25 | -9.8% | 61.8% | ||
| Q3 25 | -2.3% | 36.4% | ||
| Q2 25 | -0.1% | 18.9% | ||
| Q1 25 | -14.3% | 81.2% | ||
| Q4 24 | -121.2% | 30.8% | ||
| Q3 24 | -5.4% | -12.6% | ||
| Q2 24 | -2.3% | 67.7% |
每股收益（稀释后）EXASSLM
| Q1 26 | — | $1.54 | ||
| Q4 25 | $-0.45 | $1.11 | ||
| Q3 25 | $-0.10 | $0.63 | ||
| Q2 25 | $-0.01 | $0.32 | ||
| Q1 25 | $-0.54 | $1.40 | ||
| Q4 24 | $-4.69 | $0.53 | ||
| Q3 24 | $-0.21 | $-0.23 | ||
| Q2 24 | $-0.09 | $1.11 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $964.7M | $5.2B |
| 总债务越低越好 | — | $6.2B |
| 股东权益账面价值 | $2.4B | $2.4B |
| 总资产 | $5.9B | $29.4B |
| 负债/权益比越低杠杆越低 | — | 2.53× |
8季度趋势，按日历期对齐
现金及短期投资EXASSLM
| Q1 26 | — | $5.2B | ||
| Q4 25 | $964.7M | $4.2B | ||
| Q3 25 | $1.0B | $3.5B | ||
| Q2 25 | $858.4M | $4.1B | ||
| Q1 25 | $786.2M | $3.7B | ||
| Q4 24 | $1.0B | $4.7B | ||
| Q3 24 | $1.0B | $4.5B | ||
| Q2 24 | $946.8M | $5.3B |
总债务EXASSLM
| Q1 26 | — | $6.2B | ||
| Q4 25 | — | $5.4B | ||
| Q3 25 | — | $6.8B | ||
| Q2 25 | — | $6.4B | ||
| Q1 25 | — | $6.1B | ||
| Q4 24 | — | $6.4B | ||
| Q3 24 | — | $6.0B | ||
| Q2 24 | — | $5.4B |
股东权益EXASSLM
| Q1 26 | — | $2.4B | ||
| Q4 25 | $2.4B | $2.5B | ||
| Q3 25 | $2.5B | $2.3B | ||
| Q2 25 | $2.5B | $2.4B | ||
| Q1 25 | $2.4B | $2.4B | ||
| Q4 24 | $2.4B | $2.2B | ||
| Q3 24 | $3.2B | $2.1B | ||
| Q2 24 | $3.2B | $2.3B |
总资产EXASSLM
| Q1 26 | — | $29.4B | ||
| Q4 25 | $5.9B | $29.7B | ||
| Q3 25 | $5.9B | $29.6B | ||
| Q2 25 | $5.8B | $29.6B | ||
| Q1 25 | $5.7B | $28.9B | ||
| Q4 24 | $5.9B | $30.1B | ||
| Q3 24 | $6.7B | $30.0B | ||
| Q2 24 | $6.7B | $28.8B |
负债/权益比EXASSLM
| Q1 26 | — | 2.53× | ||
| Q4 25 | — | 2.19× | ||
| Q3 25 | — | 2.92× | ||
| Q2 25 | — | 2.70× | ||
| Q1 25 | — | 2.56× | ||
| Q4 24 | — | 2.98× | ||
| Q3 24 | — | 2.83× | ||
| Q2 24 | — | 2.37× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $151.7M | — |
| 自由现金流经营现金流 - 资本支出 | $120.4M | — |
| 自由现金流率自由现金流/营收 | 13.7% | — |
| 资本支出强度资本支出/营收 | 3.6% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $356.8M | — |
8季度趋势，按日历期对齐
经营现金流EXASSLM
| Q1 26 | — | — | ||
| Q4 25 | $151.7M | $-64.5M | ||
| Q3 25 | $219.9M | $-49.3M | ||
| Q2 25 | $89.0M | $-138.7M | ||
| Q1 25 | $30.8M | $-146.1M | ||
| Q4 24 | $47.1M | $4.5M | ||
| Q3 24 | $138.7M | $-113.4M | ||
| Q2 24 | $107.1M | $-143.8M |
自由现金流EXASSLM
| Q1 26 | — | — | ||
| Q4 25 | $120.4M | — | ||
| Q3 25 | $190.0M | — | ||
| Q2 25 | $46.7M | — | ||
| Q1 25 | $-365.0K | — | ||
| Q4 24 | $10.7M | — | ||
| Q3 24 | $112.6M | — | ||
| Q2 24 | $71.2M | — |
自由现金流率EXASSLM
| Q1 26 | — | — | ||
| Q4 25 | 13.7% | — | ||
| Q3 25 | 22.3% | — | ||
| Q2 25 | 5.8% | — | ||
| Q1 25 | -0.1% | — | ||
| Q4 24 | 1.5% | — | ||
| Q3 24 | 15.9% | — | ||
| Q2 24 | 10.2% | — |
资本支出强度EXASSLM
| Q1 26 | — | — | ||
| Q4 25 | 3.6% | — | ||
| Q3 25 | 3.5% | — | ||
| Q2 25 | 5.2% | — | ||
| Q1 25 | 4.4% | — | ||
| Q4 24 | 5.1% | — | ||
| Q3 24 | 3.7% | — | ||
| Q2 24 | 5.1% | — |
现金转化率EXASSLM
| Q1 26 | — | — | ||
| Q4 25 | — | -0.28× | ||
| Q3 25 | — | -0.36× | ||
| Q2 25 | — | -1.95× | ||
| Q1 25 | — | -0.48× | ||
| Q4 24 | — | 0.04× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -0.57× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EXAS
| Screening | $695.1M | 79% |
| Precision Oncology | $183.2M | 21% |
SLM
| Net Interest Income | $375.0M | 67% |
| Noninterest Income | $185.0M | 33% |
